Delving into the Latest Updates on SCM-181 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

人胎盘绒毛膜间充质干细胞

Target-

Mechanism-

Therapeutic Areas

Respiratory DiseasesOther Diseases

Active Indication

Idiopathic Pulmonary Fibrosis

Inactive Indication-

Originator Organization

Yunnan Shunxi Regenerative Medicine Engineering Co., Ltd.

Active Organization

Yunnan Shunxi Regenerative Medicine Engineering Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价不同剂量的SCM-181注射液静脉输注治疗特发性肺纤维化（IPF）患者的安全性和耐受性。次要目的：评价不同剂量的SCM-181注射液静脉输注治疗特发性肺纤维化（IPF）患者的初步有效性，为后续临床研究推荐合适的治疗剂量。探索性目的：探索SCM-181注射液静脉输注治疗特发性肺纤维化（IPF）患者的免疫相关指标。在多次给药剂量递增和扩展阶段将根据情况增加PK/同位素或其他探索性指标。

[Translation]

Primary objective: To evaluate the safety and tolerability of different doses of SCM-181 injection for intravenous infusion in the treatment of patients with idiopathic pulmonary fibrosis (IPF). Secondary objective: To evaluate the preliminary effectiveness of different doses of SCM-181 injection for intravenous infusion in the treatment of patients with idiopathic pulmonary fibrosis (IPF) and to recommend appropriate therapeutic doses for subsequent clinical studies. Exploratory objective: To explore the immune-related indicators of SCM-181 injection for intravenous infusion in the treatment of patients with idiopathic pulmonary fibrosis (IPF). PK/isotope or other exploratory indicators will be added as appropriate in the multiple dose escalation and expansion phases.

Start Date-

Sponsor / Collaborator

Yunnan Shunxi Regenerative Medicine Engineering Co., Ltd.

100 Clinical Results associated with SCM-181

Login to view more data

100 Translational Medicine associated with SCM-181

Login to view more data

100 Patents (Medical) associated with SCM-181

Login to view more data

100 Deals associated with SCM-181

Login to view more data